Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cefiderocol sulfate tosylate by Shionogi for Resistant Pseudomonas aeruginosa Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Resistant Pseudomonas aeruginosa Infections. According...
Cefiderocol sulfate tosylate by Shionogi for Klebsiella pneumoniae Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Klebsiella pneumoniae Infections. According to...
Cefiderocol sulfate tosylate by Shionogi for Enterobacteriaceae Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Enterobacteriaceae Infections. According to GlobalData,...
Cefiderocol sulfate tosylate by Shionogi for Acinetobacter Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Acinetobacter Infections. According to GlobalData,...
Redasemtide trifluoroacetate by Shionogi for Dilated Cardiomyopathy: Likelihood of Approval
Redasemtide trifluoroacetate is under clinical development by Shionogi and currently in Phase II for Dilated Cardiomyopathy. According to GlobalData, Phase...
S-309309 by Shionogi for Obesity: Likelihood of Approval
S-309309 is under clinical development by Shionogi and currently in Phase II for Obesity. According to GlobalData, Phase II drugs...
S-588410 by Shionogi for Non-Small Cell Lung Cancer: Likelihood of Approval
S-588410 is under clinical development by Shionogi and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
S-337395 by Shionogi for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
S-337395 is under clinical development by Shionogi and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to...
Risk adjusted net present value: What is the current valuation of Shionogi's S-309309?
S-309309 is commercialized by Shionogi, with a leading Phase II program in Obesity. According to Globaldata, it is involved in...
S-309309 by Shionogi for Obesity: Likelihood of Approval
S-309309 is under clinical development by Shionogi and currently in Phase II for Obesity. According to GlobalData, Phase II drugs...